In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

Eli Lilly LLY launched a discounted single-dose vial version of its popular obesity ... evaluating blockbuster PD-L1 inhibitor Keytruda for a type of lung cancer and skin cancer, respectively.

Eli Lilly LLY launched a discounted single-dose vial version of its popular obesity drug ... evaluating blockbuster PD-L1 inhibitor Keytruda for a type of lung cancer and skin cancer, respectively.

If approved, the introduction of the Vial Access Needle (VAN ... FDA approval to expand the use of its blockbuster cancer drug Keytruda to include the first-line treatment of patients with ...

We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. In this article, we are ...

The medication comes as a solution in a single-dose vial. Your healthcare professional ... talk with your doctor. Imfinzi and Keytruda are both prescription immunotherapy drugs used to treat ...

The overall response rate was significantly higher for Keytruda plus chemotherapy versus chemotherapy alone (52% versus 29%). The approval marks first indication for Keytruda in MPM in the US ...

Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in ...

This form of Zepbound is sold as a vial that needs to be given by a syringe, although patients can still do it themselves. Zepbound and Mounjaro are both brand names for tirzepatide. However ...